Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2016-06-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14656566.2016.1182982PMID 27267380
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

  2016cited by this paper
• Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome

  2016cited by this paper
• Irritable Bowel Syndrome: A Clinical Review.

  2016cited by this paper
• Su1378 Robustness of Eluxadoline for the Treatment of Irritable Bowel Syndrome With Diarrhea: Results From Phase 3 Composite Endpoint Assessments

  2015cited by this paper
• Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

  2015cited by this paper
• Eluxadoline: First Global Approval

  2015cited by this paper
• Irritable bowel syndrome: a clinical review.

  2015cited by this paper
• 316 Eluxadoline Demonstrates Sustained Efficacy for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome in Phase 3 Clinical Trials

  2015cited by this paper
• Su1385 Effect of Eluxadoline on Health-Related Quality of Life in Adults With Irritable Bowel Syndrome With Diarrhea: Results From Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

  2015cited by this paper
• Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis.

  2015cited by this paper
• Hunger games: is your stomach making you fat?

  2015cited by this paper
• Irritable bowel syndrome: new and emerging treatments

  2015cited by this paper
• Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications.

  2014cited by this paper
• Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers

  2014cited by this paper
• Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

  2014cited by this paper
• Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments.

  2014cited by this paper
• Irritable bowel syndrome: a microbiome-gut-brain axis disorder?

  2014cited by this paper
• Evidence-based clinical practice guidelines for irritable bowel syndrome

  2014cited by this paper
• Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome.

  2014cited by this paper
• Recent advances in pharmacological treatment of irritable bowel syndrome.

  2014cited by this paper
• Role of antispasmodics in the treatment of irritable bowel syndrome.

  2014cited by this paper
• Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome

  2014cited by this paper
• Irritable bowel syndrome: a clinical review.

  2014cited by this paper
• Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

  2014cited by this paper
• Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

  2014cited by this paper
• Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study

  2013cited by this paper
• Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

  2013cited by this paper
• Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome

  2013cited by this paper
• Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

  2012cited by this paper
• Opioid-Induced Bowel Dysfunction

  2012cited by this paper
• The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.

  2011cited by this paper
• Rifaximin therapy for patients with irritable bowel syndrome without constipation.

  2011cited by this paper
• LX‐1031, a tryptophan 5‐hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin

  2011cited by this paper
• Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study.

  2010cited by this paper
• Crofelemer, an Antisecretory Antidiarrheal Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal Chloride Channels

  2010cited by this paper
• Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences

  2010cited by this paper
• Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences

  2010cited by this paper
• Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome

  2010cited by this paper
• A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

  2009cited by this paper
• Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

  2009cited by this paper
• A Phase II Trial of the Novel Serotonin Type 3 Receptor Antagonist Ramosetron in Japanese Male and Female Patients with Diarrhea-Predominant Irritable Bowel Syndrome

  2008cited by this paper
• An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome

  2008cited by this paper
• Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial

  2008cited by this paper
• A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

  2008cited by this paper
• The role of loperamide in gastrointestinal disorders.

  2008cited by this paper
• Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients

  2008cited by this paper
• Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.

  2007cited by this paper
• FUNCTIONAL BOWEL DISORDERS

  2007cited by this paper
• Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of μ‐ and δ‐opioid receptor antagonists

  2007cited by this paper
• The Aging Gut Motility Decay: May Symbiotics Be Acting as "Implantable" Biologic Pace-Makers?

  2006cited by this paper
• Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

  2004cited by this paper
• Function of opioids in the enteric nervous system

  2004cited by this paper
• Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future

  2003cited by this paper
• A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome.

  1996cited by this paper

• Decoding Abdominal Pain in Constipation-predominant Irritable Bowel Syndrome and Functional Constipation: Mechanisms and Managements

  2025cites this paper
• Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders

  2022cites this paper
• COMPLEX OF ELUXADOLINE WITH SODIUM CAPRYLATE FOR IMPROVED SOLUBILITY AND DISSOLUTION RATE

  2021cites this paper
• Efficacy of opioid receptor modulators in patients with irritable bowel syndrome

  2021cites this paper
• Current strategies toward safer mu opioid receptor drugs for pain management

  2019cites this paper
• Antidiarrheal and Antioxidant Activities of Methanol Extract of Bryophyllum pinnatum Leaf Harvested from South-Eastern Nigeria in Mice

  2018cites this paper
• Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea

  2017cites this paper
• Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored?

  2017cites this paper
• Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.

  2017cites this paper
• Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article

  2017cites this paper
• Irritable bowel syndrome: current and emerging treatment options.

  2014cites this paper